NASDAQ: VCEL
$ 3.39 +0.03 (0.89%)
Day High: 3.42
Day Low:  3.34
Volume:    18,400
4:00 PM ET on
Jul 31, 2015

Delayed ~20 min., by eSignal.

Press Releases

 
Press Releases
  Date Title View
Jul 29, 2015
CAMBRIDGE, Mass., July 29, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: ...
Jul 14, 2015
CAMBRIDGE, Mass., July 14, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that following discussions with the U.S. Food and Drug Administration (FDA), the company plans to submit a Humanitarian Device...
Jun 10, 2015
CAMBRIDGE, Mass., June 10, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that following discussions with the U.S. Food and Drug Administration (FDA) the company plans to submit a Biologics License Ap...
May 14, 2015
Total Revenues of $10.8 Million Reported for the First Quarter Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today reported financial result...
Apr 30, 2015
CAMBRIDGE, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: What: Vericel Corporation First-Quarter 2015 Earnings Call Wh...
Apr 8, 2015
CAMBRIDGE, Mass., April 8, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will present a corporate update at the 14th Annual Needham Healthcare Conference at 4:20 pm Eastern time on Wednesday,...
Mar 25, 2015
CAMBRIDGE, Mass., March 25, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today reported that positive results from the three-year extension of the Phase 3 SUMMIT study with MACI™ (matrix-applied characterized...
Mar 23, 2015
Total Revenues of $14.7 Million Reported for the Fourth Quarter Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., March 23, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today reported financial res...
Mar 18, 2015
CAMBRIDGE, Mass., March 18, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will present at the following investor conferences later this month: Canaccord Genuity Musculoskeletal Conferenc...
Mar 12, 2015
CAMBRIDGE, Mass., March 12, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following conference call and webcast: What: Vericel, Inc., Fourth Quarter 2014 Earnings Call When: ...
1
... NextLast
= add release to Briefcase